The Cancer Letter Archives
The Cancer Letter was founded in 1973, two years after Congress passed the National Cancer Act of 1971. These archives represent the first 40 years of The Cancer Letter, which is published weekly.
CCL
Vol.
34
No.
10
October 28, 2011
- Herceptin Regimen Minus Adriamycin Increases Survival With Less Toxicity
- Alimta Reduces Risk Of Progression In Patients Aged 70 Years or Older
- Family History of BRCA Mutation Does Not Equal Increased Risk
- Daily Vitamin E Supplements Can Lead to Increased PCa Risk
- Digital Immunoassay PSA Test May Predict Cancer Recurrence
- Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV
- Researchers Discover Bacteria Common in Colon Cancer Tissue
- Colon Cancer Survival Rates Differ Across Racial Lines
- NCI Predicts 42 Percent Increase In Number of Senior Survivors
- IMRT Less Toxic Than 3D-CRT In Localized Prostate Cancer
- NCI CTEP: Approved Trials For The Month of October
- FDA Grants Accelerated Approval To Ferriprox for Iron Overload
TCL
Vol.
37
No.
Nov 18 special report
November 18, 2011
TCL
Vol.
37
No.
43
November 18, 2011
- ACS Creates $1 Billion Nationwide Organization, Taking Fiduciary Control From 12 Divisions
- With No Budget in Sight, NCI Takes Careful Steps; Success Rate Last Year Was 14 percent
- FDA Revokes Avastin’s Accelerated Approval In Metastatic Breast Cancer Indication
- Industry Groups Lobby for Lower Standards for FDA Approval
CCL
Vol.
34
No.
11
November 25, 2011
- ADT Does Not Raise Risk of Heart Attacks In Men With No History Of Heart Disease
- Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint
- MDV3100 Improves Survival, Reduces Death Risk by 37%
- Xgeva Delays Metastases To Bone, Amgen Files To Expand Indication
- Elevated Baseline Glucose Levels Associated With Higher Cancer Risk
- Oncotype DX Cancer Test Can Predict Recurrence
- Signet Cell A Rising Trend In Patients Under Age 40
- FIT More Effective Than gFOBT In All Colonoscopy Capacities
- Tumor Treating Fields Therapy Increased Three-Year Survival
- Only 20 Percent Of At-Risk Patients Are Screened For HBV Before Therapy
- New Algorithm Completes Scan Three Times Faster Than Before
- Survivorship Studies Unfocused As Total Research Increases
- Trials Approved by NCI CTEP Last Month
- Agency Approves HPV Test That Detects 14 High-Risk Strains
- Alimta Granted Approval As NSCLC Continuation Therapy